ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Was hoping a slight Increase today but Nothing

<< Previous

Bullboard Posts

Next >>

Post by azzymaaon Jun 27, 2022 11:50am

258 Views

Post# 34784793

Was hoping a slight Increase today but Nothing

Why is Promis so content on listing on the Nasdaq when they have no real news to portray? The SP is unchanged and after the RS the SP will surely tank. How will they maintain a 4.00 US minimum for the next 4-6 weeks? Feel sorry for the long term holders and how they will lose half of their holdings. Very bad management and a only the insiders will prosper. Pathetic company.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity